Facebook
Instagram
Pinterest
Reddit
Tumblr
X
Youtube
Home
About
News
Events
Shop
Directory
Contact Us
Search
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Password recovery
Recover your password
your email
A password will be e-mailed to you.
PsyNews.com
Home
About
News
Events
Shop
Directory
Contact Us
Home
Featured
Page 146
Featured
Latest
Latest
Featured posts
Most popular
7 days popular
By review score
Random
Pα+ Psychedelic Bulletin #233: FDA Floats Ibogaine Trial Design; Compass Talks Pricing; Potential LSD, Psilocybin Brand Names
Kenneth Tupper, PhD: Harm Reduction, Drug Education, Canadian Ayahuasca, and Psychedelic Public Health
Weekly Psychedelic Policy Briefing: October 5, 2026
Podcast: Oregon Backtracks on Fee Hike, California Funds Psychedelic Research, DEA Moves to Schedule 5 Tryptamines
Psychedelic Churches Need Psychedelic Seminaries
Israel-Based Clearmind Medicine Shows Efficacy of Psychedelic- Derived Obesity Treatment in...
Confirmatory Phase 3 Trial of MDMA Therapy for PTSD is “Successful”,...
Algernon Pharmaceuticals Forms Private Subsidiary to Advance Company’s Psychedelic DMT Stroke...
PT380 – Microdosing, Talking to Physicians About Psychedelics, and Nurses as...
Psychedelics Weekly – Psilocybin and Stress Response, the Minnesota Medical Association...
Clearmind Medicine Announces Shareholders Meeting Results
Israel-Based Clearmind Medicine Announces First Clinical Center to Join Its Clinical...
PT379 – Intergenerational Trauma, Late-Stage Capitalism, and the Urban Indigenous Collective
Small Pharma Announces Completion of SPL026 Phase IIa Trial and Secures...
Revive Therapeutics Announces Submission of Type C Meeting Request to FDA...
Load more